KBIO News Alert Kalobios Pharmaceuticals Inc (KBIO) 1.63 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Kalobios Pharmaceuticals Inc (KBIO) 1.63 $KBIO

Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 1.63 (-0.04), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), ONTX: 3.82 (+0.06), CTIC: 2.36 (+0.05), BMY: 59.15 (-0.01), STML: 15.53 (+0.23), NVS: 93.91 (+0.66), MEIP: 3.90 (+0.11), CELGZ: 3.34 (-0.01), XLRN: 38.80 (+0.80)

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 104.59 (+0.31), KBIO: 1.63 (-0.04), PFE: 31.42 (-0.03), ADMP: 5.17 (+0.06), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66), FPRX: 26.12 (+0.07)

KaloBios names Robert A. Baffi to board
M2 - Mon Dec 01, 7:32AM CST
Monoclonal antibodies company KaloBios Pharmaceuticals (NasdaqGM:KBIO) revealed on Monday the addition of Dr. Robert A. Baffi, Ph.D. to its board of directors.
BMRN: 88.18 (+0.89), KBIO: 1.63 (-0.04)

KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors
PR Newswire - Mon Dec 01, 7:05AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the election of Robert A. Baffi, Ph.D. to the KaloBios Board of Directors. Dr. Baffi is Executive Vice President of Technical Operations at BioMarin Pharmaceutical Inc. (Nasdaq: BMRN).
BMRN: 88.18 (+0.89), KBIO: 1.63 (-0.04)

Akorn (AKRX) Worth Watching: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 7:51AM CST
Akorn, Inc. (AKRX) was a big mover last session, as its shares rose over 6% on the day.
MNK: 97.84 (-0.29), KBIO: 1.63 (-0.04), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)

KaloBios Announces Upcoming Scientific and Investor Conference Participation
PR Newswire - Tue Nov 11, 3:05PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the Stifel 2014 Healthcare Conference in November, and that data on the company's KB004 program in hematologic malignancies will be presented in a poster session at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in early December.
KBIO: 1.63 (-0.04)

KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 97.84 (-0.29), IPXL: 31.32 (+0.26), KBIO: 1.63 (-0.04), MYL: 56.97 (+0.39)

KaloBios Pharmaceuticals beats by $0.10
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:38PM CST

KBIO: 1.63 (-0.04)

KaloBios Reports Third Quarter Financial Results
PR Newswire - Thu Nov 06, 3:05PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today reported its financial results for the third quarter of 2014.
KBIO: 1.63 (-0.04)

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), ONTX: 3.82 (+0.06), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), STML: 15.53 (+0.23), SNTA: 2.63 (+0.02), KBIO: 1.63 (-0.04), BPTH: 2.80 (+0.03), CELGZ: 3.34 (-0.01), NVS: 93.91 (+0.66)

NeoStem Announces Additions to Management
GlobeNewswire - Wed Nov 05, 6:46AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a biopharmaceutical company developing novel cell based therapeutics, announced today the addition of three experienced leaders in the biotech industry to its management team. Harry Lam, Ph.D., Ann M. Daus, Ph.D., and Anna Crivici, Ph.D. bring a breadth of experience in leading high performing teams to meet operational goals.
KBIO: 1.63 (-0.04), NBS: 3.27 (+0.02)

Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST

FRM: 7.61 (unch), NEO: 4.03 (-0.10), AU: 8.39 (+0.24), FNHC: 25.30 (+0.45), AMS: 2.50 (-0.02), NYMX: 0.38 (unch), AMDA: 0.64 (-0.01), CVD: 103.73 (+0.02), GBIM: 7.29 (unch), RCAP: 11.23 (+0.26), KBIO: 1.63 (-0.04), COOL: 1.15 (+0.14), SAPE: 24.81 (-0.01), XTLB: 2.21 (+0.03), GERN: 3.06 (+0.05), ANIP: 55.24 (+1.79), BBLU: 1.15 (-0.03), NXTD: 2.46 (-0.09), AP: 19.03 (+0.47), ALQA: 3.96 (-0.02)

Cerulean Pharma (CERU) Worth Watching: Stock Soars 30.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:25AM CDT
Cerulean Pharma (CERU) was a big mover last session, with shares surging nearly 31% on the day.
MNK: 97.84 (-0.29), KBIO: 1.63 (-0.04), AKRX: 36.47 (+0.43), CERU: 6.45 (unch)

Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy
PR Newswire - Thu Aug 14, 7:00AM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the publication of preclinical findings describing EphA3 as a novel target expressed by a broad range of human tumors, and whose activation can lead to the selective disruption of the tumor microenvironment and newly formed tumor blood vessels. The expression and function of EphA3 in the tumor microenvironment but not in adult normal tissues together with the favorable safety profile as observed thus far in a Phase 1-2 clinical study, where infusion reactions have been the most common adverse event, supports the development of KB004 (KaloBios' Humaneered® anti-EphA3 monoclonal antibody [mAb]) as a potential treatment for both hematologic and solid tumors.
KBIO: 1.63 (-0.04)

KaloBios (KBIO) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 9:04AM CDT
KaloBios (KBIO) Enters Oversold Territory
KBIO: 1.63 (-0.04)

Relypsa (RLYP) Worth Watching: Stock Gains 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 8:46AM CDT
Relypsa (RLYP) was a big mover last session, with shares rising over 13% on the day.
MNK: 97.84 (-0.29), KBIO: 1.63 (-0.04), AKRX: 36.47 (+0.43), RLYP: 30.35 (-0.22)

KaloBios Provides Clinical Update and Reports Second Quarter Financial Results
PR Newswire - Thu Aug 07, 7:00AM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on its current clinical programs and announced financial results for the second quarter of 2014.
KBIO: 1.63 (-0.04)

KaloBios Provides Update on KB001-A Partnership and Clinical Status
PR Newswire - Mon Jul 28, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of the KB001-A development program, including an update on its KB001-A collaboration with Sanofi Pasteur.
KBIO: 1.63 (-0.04)

Cutera, Inc. (CUTR) in Focus: Stock Adds 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:11AM CDT
Cutera, Inc. (CUTR) was a big mover last session, as the company saw its shares rise over 7% on the day.
KBIO: 1.63 (-0.04), AKRX: 36.47 (+0.43), AERI: 29.49 (+1.23), CUTR: 9.98 (-0.01)

5 Stocks Under $10 Setting Up to Soar
at The Street - Thu Jun 26, 12:56PM CDT
These under-$10 stocks look poised to break out and trade higher from current levels.
HEAR: 2.98 (+0.01), NWBO: 5.58 (+0.04), KBIO: 1.63 (-0.04), SFUN: 7.17 (-0.03), ONTX: 3.82 (+0.06), PRAN: 1.74 (-0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 73

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 21

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 44

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 96

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 40

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking AI Potential: VERSES Genius™ Surpasses Competitors

Updated Category News Views 353

VERSES Genius™ Agent Sets New Benchmark in AI Performance VERSES AI Inc., a pioneer in cognitive computing, is redefining intelligent systems with its innovative Genius™ toolkit. Recent evaluations against industry-leading benchmarks highlight its significant advancements in artificial intelligence. The preliminary results regarding the "Atari 100K Challenge" showcase...

Continue Reading
MKS Instruments Achieves Loan Repricing and Adds Prepayment

Updated Category News Views 356

MKS Instruments Achieves Loan Repricing and Adds Prepayment MKS Instruments, Inc. (NASDAQ: MKSI), a prominent global leader in enabling technologies, has made a significant leap in optimizing its financial structure. Recently, the company announced it has completed the repricing of its considerable secured tranche B term loans, which amount to a staggering $2.5 billion...

Continue Reading
Incredible Growth of Cheniere Energy: A 15-Year Journey

Updated Category News Views 238

The Remarkable Performance of Cheniere Energy Cheniere Energy, known by its trading symbol LNG, has consistently outperformed the market over the past 15 years. Investors in LNG have witnessed an incredible annualized return of 35.23%, exceeding the market by 22.77%. Currently, Cheniere Energy boasts a market capitalization of $53.26 billion, marking its growth trajectory...

Continue Reading
Adhara and ioBuilders Form New Powerhouse in Blockchain Solutions

Updated Category News Views 420

Adhara and ioBuilders Unite for Blockchain Innovation Adhara and ioBuilders have merged their expertise to create a leading provider of blockchain software products tailored specifically for financial institutions. This strategic alliance has resulted in a profitable company with a robust workforce of over 120 employees, distributed across various regions including the...

Continue Reading
Legal Action Against Lineage, Inc. Following Significant Stock Drop

Updated Category News Views 227

Overview of the Situation Surrounding Lineage, Inc. In recent times, Lineage, Inc. has found itself at the heart of a significant legal controversy following a dramatic 17% drop in its stock price. Leading with this news is the announcement of a class action lawsuit against the company and some of its top executives. Legal firm Bleichmar Fonti & Auld LLP is rallying...

Continue Reading